Maze Therapeutics looks for IPO lodestar to guide kidney disease assets through clinical trials
Just a month after announcing a $115 million series D financing to advance its lead assets, Maze Therapeutics is looking to boost its kidney disease candidates further by going public. | Just a month after announcing a $115 million series D to advance its lead assets,